German pharmaceutical and nutraceutical-focused CDMO, 1Q Health, has acquired contract research organisation (CRO), VivaCell Biotechnology.
This follows the company's launch in November 2024, championed by CEO Philipp Ziehr.
Founded in 2003, VivaCell has more than two decades of experience, offering both in vitro and ex vivo ingredient testing and development services — spanning the realm of pharmaceuticals, functional foods and nutraceuticals.
Based in Spain, the wholly-owned subsidiary of US-based Emerald Health Sciences has built a significant customer base within the European market, offering its clinical-stage synthethic drug discovery and development services to address key unmet medical needs.
Focused primarily on the treatment of vascular and neurodegenerative diseases, VivaCell will significantly bolster 1Q Health's testing and development offerings, allowing its customers to "scientifically prove the health benefits, safety and bioactivity of their products, setting them apart from competitors," the company notes in a news announcement.
1Q Health's acquisition of VivaCell Biotechnology follows the company's recent stream of mergers with both pharmaceutical and nutraceutical companies, including:
- HKS Health Solutions: An Austria-based supplement CDMO offering a wide range of services such as packaging, logistics, shipping, development and small to medium batch manufacturing
- Dronania Pharmaceuticals: A German CDMO specialising in the GMP production of liquid, tablet and capsule botanical supplements. The company also offers its clients development and laboratory services
- ABJ Alive: A hard capsule manufacturing specialist based in the German town of Bayreuth, ABJ Alive also holds significant expertise in the processing of plant extracts and probiotics.